This contract expires in 189 days (Jan 13, 2027).
THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO - DETERMINATION OF THE IN VITRO ACTIVITY OF EXPERIMENTAL ANTIFUNGAL SUBSTANCES AGAINST FUNGAL PATHOGENS, INCLUDING THE FUNGAL SPECIES IDENTIFIED IN TABLE 1 BELOW, AS WELL AS TOXICITY OF A SUBSET OF THESE ANTIFUNGAL SUBSTANCES IN MAMMALIAN CELL ASSAYS.
Key Details
Description
DETERMINATION OF THE IN VITRO ACTIVITY OF EXPERIMENTAL ANTIFUNGAL SUBSTANCES AGAINST FUNGAL PATHOGENS, INCLUDING THE FUNGAL SPECIES IDENTIFIED IN TABLE 1 BELOW, AS WELL AS TOXICITY OF A SUBSET OF THESE ANTIFUNGAL SUBSTANCES IN MAMMALIAN CELL ASSAYS.
Context & Analysis
On Jan 14, 2026, Department of Health and Human Services obligated $91,308.51 to THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO for determination of the in vitro activity of experimental antifungal substances against fungal pathogens, including the fungal species identified in table 1 below, as well as toxicity of a subset of thes…. The award is classified under NAICS 541714 — RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY) and issued as a firm fixed price contract. Competition extent: full and open competition with 1 offer received. Performance is located in SAN ANTONIO, TX. The contract is scheduled through Jan 13, 2027 — approximately 6 months remaining. This award is one of several similar procurements from Department of Health and Human Services under NAICS 541714 — related awards are listed below.
Contractor Information
Similar Awards
CLINICAL SERVICES NETWORK- CLINICAL TRIAL PLANNING AND EXECUTION
ALLUCENT GOVERNMENT SERVICES (US) LLC
$370.1M
CLINICAL SERVICES NETWORK- CLINICAL TRIAL PLANNING AND EXECUTION
ICON GOVERNMENT AND PUBLIC HEALTH SOLUTIONS, INC.
$330.2M
CLINICAL SERVICES NETWORK- CLINICAL TRIAL PLANNING AND EXECUTION
TECHNICAL RESOURCES INTERNATIONAL, INC.
$317.1M
ANTIBIOTIC FOR TREATMENT OF A BIOTHREAT INDICATION
PARATEK PHARMACEUTICALS, INC
$265.3M
ASPR-18-04963 -- FUNDING FOR BALOXAVIR MARBOXIL ACTIVITIES FOR BASE PERIOD TASK UNDER THE GENENTECH OTA
GENENTECH INC
$243.7M
Stay Updated
Get notified about new opportunities matching your interests.